Ximelagatran Cost Effectiveness for Stroke Prevention in Atrial Fibrillation

E-ISSN： 2055-2335|35|4|279-283

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.35, Iss.4, 2005-12, pp. : 279-283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ximelagatran reduces stroke risk in atrial fibrillation

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US

By Sullivan Patrick W.

PharmacoEconomics, Vol. 24, Iss. 10, 2006-01 ,pp. : 1021-1033

Adis International

Access to resources Recommend Favorite

Dronedarone: A New Hope for Stroke Prevention in Atrial Fibrillation?

By Shantsila Alena Lip Gregory Y.H.

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. : 355-356

Adis International

Access to resources Recommend Favorite

Stroke Prevention in Atrial Fibrillation: Putting the Guidelines into Practice

By Mant Jonathan Edwards Duncan

Drugs & Aging, Vol. 27, Iss. 11, 2010-11 ,pp. : 859-870

Adis International

Access to resources Recommend Favorite

Guidelines for Stroke Prevention in Patients with Atrial Fibrillation

By Howard P.A.

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 997-1009

Adis International

Access to resources Recommend Favorite